1. Home
  2. PRAX vs BRKR Comparison

PRAX vs BRKR Comparison

Compare PRAX & BRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$327.34

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Logo Bruker Corporation

BRKR

Bruker Corporation

HOLD

Current Price

$39.25

Market Cap

5.5B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
BRKR
Founded
2015
1960
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
5.5B
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
PRAX
BRKR
Price
$327.34
$39.25
Analyst Decision
Strong Buy
Buy
Analyst Count
15
13
Target Price
$572.13
$49.54
AVG Volume (30 Days)
364.5K
2.3M
Earning Date
05-12-2026
05-04-2026
Dividend Yield
N/A
0.51%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,895,600,000.00
Revenue This Year
N/A
$5.75
Revenue Next Year
$6,395.88
$3.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.70
$28.53
52 Week High
$354.87
$56.22

Technical Indicators

Market Signals
Indicator
PRAX
BRKR
Relative Strength Index (RSI) 53.03 39.94
Support Level $290.36 $35.70
Resistance Level N/A $42.89
Average True Range (ATR) 18.07 1.79
MACD -2.63 0.30
Stochastic Oscillator 55.61 59.95

Price Performance

Historical Comparison
PRAX
BRKR

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About BRKR Bruker Corporation

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

Share on Social Networks: